Ecs Botanics Holdings Ltd · ASX:ECS
Ecs Botanics — ASX Small – Mid Cap Conference 2024
21 slides from Ecs Botanics's conference presentation, Sep 25, 2024
Slide 1: ECS Botanics Holdings Ltd Corporate Presentation
For personal use only C O R P O R A T E P R E S E N T A T I O N ECS Botanics Holdings Ltd A leading organic cultivator and manufacturer of medicinal cannabis ASX Small – Mid Cap Conference ASX : ECS 25 September 2024
Slide 2: Capital Structure
Capital Structure Market capitalisation Share price Board & Management ownership Top 20 ownership For personal use only A$20.6m $0.018 9.2% 35.9% I N V E S T O R As at 18 Sep 2024 As at 18 Sep 2024 As at 18 Sep 2024 As at 18 Sep 2024 52 week high $0.031, low $0.013 Shares on issue Listed options (EC
Slide 3: Corporate History
Corporate History Rapidly Growing, Profitable Medicinal Cannabis Cultivator. For personal use only Established in 2018 as an ASX-listed company with a Tasmanian-based Food and I N V E S T O R Wellness business Acquired Murray Meds in March 2021, licensed in 2020 Initial focus on extraction but
Slide 4: Corporate Highlights
Corporate Highlights Production in tonnes Diversified Sales Expanding Production For personal use only E Q U I I NT VY E S • Diversified white label and own • Ideally located in NW Victoria FY22 2.8 brand • Licensed to produce 13 tonnes • Export forecast to be 32% of FY23 4.2 • TGA/GMP Pharmaceutica
Slide 5: Corporate Highlights: Innovation, Sustainability and Governance
Revenue and COGS Corporate Highlights Sustainability and Governance Innovative For personal use only E Q U I I NT VY E S • Certified Organic • VESIsorb high bioavailability excipient licensed for 10 years • Sun and Soil grown launching in Q2 FY25 • Renewable energy • Terphogz licensed for 8 years •
Slide 6: The Addressable Market
The Addressable Market Cannabis market globally is still in an emerging phase with strong growth potential. 2023 $0.6 For personal use only Australia2 MEDICAL CANNABIS MARKET billion 20.0 Australia I N V E S T O R ($USD Billions) USA $594m 26m $22 Establishing 28.0 Europe Legal Med Cannabis Populati
Slide 7: Doctors Looking For Alternatives
Doctors Looking For Alternatives. “ One of the world’s worst public health crises ” For personal use only Opioids and Benzodiazepines not only cause deaths but also destroy lives. John Ryan Pennington 6 Australians lose their life to overdose everyday Institute CEO I N V E S T O R THC and CBD is a s
Slide 8: Partnering with the Best
Partnering with the Best Successful expansion into exports. For personal use only Agreements in place with customers I N V E S T O R across the globe Customers include global brands like Ilios Santė (Germany), Curaleaf (UK), Koyi (Poland), and Nubu (NZ) P R E S E N T A T I O N European custome
Slide 9: Partnering with the Best: Terphogz
Partnering with the Best Terphogz . For personal use only • ECS will manufacture and supply under I N V E S T O R exclusive eight-year license, a range of Terphogz products for distribution in Germany, Australia and New Zealand • Terphogz range - including Zkittlez (The P R E S E N T A T I O N Origi
Slide 10: Track Record of Financial Performance
Track Record of Financial Performance Scaling revenue and earnings. Strong balance sheet. For personal use only Revenue vs COGS EBITDA BALANCE SHEET 30-Jun-24 30-Jun-23 25 4 I N V E S T O R Cash 3.2 2.5 3 20 2 Total Assets 32.9 26.1 1 15 0 Current financial liabilities (3.9) (3.7) P R E S E N T A T
Slide 11: ECS Model
ECS Model Profitable Operations. Key FY24 Comparative Metrics For personal use only Ideal Location Leveraging the sun and soil reducing I N V E S T O R Competitors Financial energy and fertiliser costs Performance (in A$ million) $30.4 Asset Lite $20.5 $25.6 $19.1 High return on capital employed P R
Slide 12: Strategic Roadmap
Strategic Roadmap Delivering on a Clear Strategy to Drive Value. For personal use only 2018-2020 2021-2023 2024-2026 2027-2029 M A Y Developing Capability Focused, Expanding Drive Profitability, Leading Australian and Confidence and Growing Revenue Innovation and Expansion Medicinal Cannabis 2 0 2 4
Slide 13: The Cultivation Advantage
The Cultivation Advantage Location and Assets Production Profile For personal use only • 9 New PCEs being constructed, increasing production I N V E S T O R capacity by 3.6T • Additional heating and lighting in 6 existing PCE's will produce a further 1.2T • Improvements in genetics will increase yie
Slide 14: Building out B2C offering
Building out B2C offering Quality Team & Product Range. For personal use only B2C model based on selling the I N V E S T O R advantages of ECS products to prescribers/general practitioners ECS Botanics product range now includes Oils, Dried Flower, Vapes, Gummies, Soft Gel Capsules, VESIsorb
Slide 15: Investment Highlights
Investment Highlights Contracted ~ A$60m in 24 months, with further expansion required to meet market demand Expand GMP manufacturing facility to process volumes Scaling revenue For personal use only Constructing 9 new PCE’s to meet licensed production capacity (bringing total PCEs to 26) On
Slide 16: Appendices
E C S B O T A N I C S H O L D I N G S L T D APPENDICES For personal use only I N V E S T O R P R E S E N T A T I O N 16
Slide 17: ESG Credentials
ESG Credentials. For personal use only I N V E S T O R Regenerative, organic Location reduces farming means lower energy required for fertilizer and soil Cannabis production amendments as soil due to high daylight regenerates and intervals. P R E S E N T A T I O N captures carbon. Strong Community S
Slide 18: ECS Board and Leadership
ECS Board and Leadership. For personal use only I N V E S T O R Jeremy King Nan-Maree Schoerie Michael Nitsche Dr Rachel Swift Arthur Sun Nicholas Thomas Non-Executive Director Non-Executive Director Chief Operating Officer P R E S E N T A T I O N Non-Executive Chairman Managing Director Chief Finan
Slide 19: ECS Medical Advisory Board
ECS Medical Advisory Board. For personal use only I N V E S T O R Dr Charlotte Middleton Dr Natasha Feingold Dr Chris Schneider Dr Rupert Backhouse Dr Justin Welsh Dr Phil Burrell P R E S E N T A T I O N Dr. Middleton is an Dr. Feingold is a GP at Her Dr. Schneider is a Dr. Backhouse is a GP in Dr.
Slide 20: Disclaimer
Disclaimer For personal use only This presentation has been prepared by ECS Botanics recommendation in relation to the purchase or sales of contractors or agents about the accuracy, completeness I N V E S T O R Holdings Limited (“Company”). shares or other securities in any jurisdiction. or fairness
Slide 21: Contact Us
E C S B O T A N I C S H O L D I N G S L T D Contact Us For personal use only I N V E S T O R P R E S E N T A T I O N Call us today at Email us at 1300 833 988 info@ecs-botanics.com Investor Relations eric.kuret@automicgroup.com.au VISIT US E C S - B O T A N I C S . C O M ECS BOTANICS HOLDINGS LTD 21
ECS Botanics Holdings — ASX Small – Mid Cap Conference 2024 on 6ix